The assay is able to discriminate healthy individuals (i.e., WT-ATM alleles; p53-MCL >75%) from typical AT patients (i.e., biallelic ATM mutations; p53-MCL <30%) and from AT healthy carriers (i.e., monoallelic ATM mutations; p53-MCL >40% < 65%) (Prodosmo et al., 2013). This evidence concerns the gene ATM and ataxia telangiectasia.